EP3897647
COMBINATIONS OF A HDM2-P53 INTERACTION INHIBITOR AND A BCL2 INHIBITOR AND THEIR USE FOR TREATING CANCER
:
EP einkaleyfi: Þýðing ekki lögð inn:
18.12.2019:
1.11.2023:
19835803.8
:
17.12.2039
:
COMBINATIONS OF A HDM2-P53 INTERACTION INHIBITOR AND A BCL2 INHIBITOR AND THEIR USE FOR TREATING CANCER
18.12.2019
1.11.2023
:
Novartis AG:
Lichtstrasse 35, 4056 Basel, CH
:
GUERREIRO, Nelson:
4002 Basel, CH
:
HALILOVIC, Ensar:
Cambridge, Massachusetts 02139, US
:
JULLION, Astrid:
4002 Basel, CH
:
MEILLE, Christophe:
4002 Basel, CH
:
WANG, Youzhen:
Cambridge, Massachusetts 02139, US
:
FABRE, Claire:
4002 Basel, CH
:
201862782727 P:
20.12.2018:
US
:
201862782730 P:
20.12.2018:
US
:
201862782735 P:
20.12.2018:
US
:
IB2019061014:
18.12.2019
:
A61K 31/506, A61K 31/635, A61K 39/395, A61K 45/06, A61P 35/02, C07K 16/28